Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

NCT04175522 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Green Cross Corporation